BioCentury | Sep 19, 2020
Finance

Athira, Compass IPOs help quartet push biopharmas’ 2020 NASDAQ haul above $9B

...companies filing this month to list on NASDAQ (see “Data Byte: IPO Queue”).The offering by Athira Pharma Inc....
...SPAC Merger Yet”).TARGETSHGF/SF - Hepatocyte growth factor/scatter factorMET (c-MET; HGFR) - c-Met receptor tyrosine kinase Paul Bonanos Athira Pharma Inc. Compass...
BioCentury | Aug 29, 2020
Finance

Aug. 28 Quick Takes: Synthego raises $100M D round, plus Clene, Aetion, Antengene, Athira, Compass

...exchange. Goldman Sachs and J.P. Morgan will underwrite the Shanghai-based cancer company’s IPO.Athira joins IPO queue Athira Pharma Inc....
...COMP360, a high-purity polymorphic crystalline formulation of psilocybin, for treatment-resistant depression. BC Staff Synthego Corp. Clene Nanomedicine Inc. Antengene Corp. Athira Pharma Inc. Compass...
BioCentury | Aug 5, 2020
Management Tracks

CureVac makes Haas’ CEO job permanent; plus Zhang now CEO of Legend and updates from Royalty, NBE, Black Diamond, VelosBio and more

...Thomson as general counsel. Before joining the myelofibrosis, she served in the same role at Athira Pharma Inc....
BioCentury | Jun 5, 2020
Finance

With $85M series B, Athira seeks to recover neuronal health in Alzheimer’s patients

...thinks could not only slow disease progression, but also improve cognitive function. Perceptive Advisors led Athira Pharma Inc.’s...
...tyrosine kinase Elizabeth S. Eaton, Staff Writer c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) Hepatocyte growth factor/scatter factor (HGF/SF) Athira Pharma Inc....
BioCentury | May 2, 2019
Company News

Management tracks: Akero, NIH, Arcus

...CTO. He was COO of Nohla Therapeutics Inc. (Seattle, Wash.). Neurodegenerative disease company Athira Pharma Inc. (formerly M3 Biotechnology...
...manufacturer Endodynamix Inc., which Conmed Corp. (NASDAQ:CNMD) acquired. BioCentury Staff Akero Therapeutics Inc. Arcus Biosciences Inc. Arcutis Inc. NIH Rainier Therapeutics Inc. Athira Pharma Inc. Vivera...
BioCentury | Apr 20, 2017
Financial News

M3 Biotechnology completes venture financing

...On April 14, neurodegenerative disease company M3 Biotechnology Inc. (Seattle, Wash.) raised $1.4 million in a venture...
...million in a venture financing from Alzheimer’s Drug Discovery Foundation. M3 Biotechnology Inc. , Seattle, Wash. Alicia Parker M3 Biotechnology...
BioCentury | Feb 15, 2016
Financial News

M3 Biotechnology completes venture financing

M3 Biotechnology Inc. , Seattle, Wash. Business: Neurology Date completed: 2016-02-11 Type: Venture financing Raised: $10 million Investors: WRF Capital; W Fund; private investors WIR Staff Neurology...
BioCentury | Feb 12, 2016
Financial News

M3 raises $10M in series A

M3 Biotechnology Inc. (Seattle, Wash.) raised $10 million in an oversubscribed series A round. Brothers Bruce and Michael Montgomery invested alongside W-Fund, WRF Capital, John Fluke and Dolby Family Ventures. CEO Leen Kawas told BioCentury...
Items per page:
1 - 8 of 8
BioCentury | Sep 19, 2020
Finance

Athira, Compass IPOs help quartet push biopharmas’ 2020 NASDAQ haul above $9B

...companies filing this month to list on NASDAQ (see “Data Byte: IPO Queue”).The offering by Athira Pharma Inc....
...SPAC Merger Yet”).TARGETSHGF/SF - Hepatocyte growth factor/scatter factorMET (c-MET; HGFR) - c-Met receptor tyrosine kinase Paul Bonanos Athira Pharma Inc. Compass...
BioCentury | Aug 29, 2020
Finance

Aug. 28 Quick Takes: Synthego raises $100M D round, plus Clene, Aetion, Antengene, Athira, Compass

...exchange. Goldman Sachs and J.P. Morgan will underwrite the Shanghai-based cancer company’s IPO.Athira joins IPO queue Athira Pharma Inc....
...COMP360, a high-purity polymorphic crystalline formulation of psilocybin, for treatment-resistant depression. BC Staff Synthego Corp. Clene Nanomedicine Inc. Antengene Corp. Athira Pharma Inc. Compass...
BioCentury | Aug 5, 2020
Management Tracks

CureVac makes Haas’ CEO job permanent; plus Zhang now CEO of Legend and updates from Royalty, NBE, Black Diamond, VelosBio and more

...Thomson as general counsel. Before joining the myelofibrosis, she served in the same role at Athira Pharma Inc....
BioCentury | Jun 5, 2020
Finance

With $85M series B, Athira seeks to recover neuronal health in Alzheimer’s patients

...thinks could not only slow disease progression, but also improve cognitive function. Perceptive Advisors led Athira Pharma Inc.’s...
...tyrosine kinase Elizabeth S. Eaton, Staff Writer c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) Hepatocyte growth factor/scatter factor (HGF/SF) Athira Pharma Inc....
BioCentury | May 2, 2019
Company News

Management tracks: Akero, NIH, Arcus

...CTO. He was COO of Nohla Therapeutics Inc. (Seattle, Wash.). Neurodegenerative disease company Athira Pharma Inc. (formerly M3 Biotechnology...
...manufacturer Endodynamix Inc., which Conmed Corp. (NASDAQ:CNMD) acquired. BioCentury Staff Akero Therapeutics Inc. Arcus Biosciences Inc. Arcutis Inc. NIH Rainier Therapeutics Inc. Athira Pharma Inc. Vivera...
BioCentury | Apr 20, 2017
Financial News

M3 Biotechnology completes venture financing

...On April 14, neurodegenerative disease company M3 Biotechnology Inc. (Seattle, Wash.) raised $1.4 million in a venture...
...million in a venture financing from Alzheimer’s Drug Discovery Foundation. M3 Biotechnology Inc. , Seattle, Wash. Alicia Parker M3 Biotechnology...
BioCentury | Feb 15, 2016
Financial News

M3 Biotechnology completes venture financing

M3 Biotechnology Inc. , Seattle, Wash. Business: Neurology Date completed: 2016-02-11 Type: Venture financing Raised: $10 million Investors: WRF Capital; W Fund; private investors WIR Staff Neurology...
BioCentury | Feb 12, 2016
Financial News

M3 raises $10M in series A

M3 Biotechnology Inc. (Seattle, Wash.) raised $10 million in an oversubscribed series A round. Brothers Bruce and Michael Montgomery invested alongside W-Fund, WRF Capital, John Fluke and Dolby Family Ventures. CEO Leen Kawas told BioCentury...
Items per page:
1 - 8 of 8